Brief: Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC Filing

Filana Therapeutics

03/12/2025 12:51

Dec 3 (Reuters) - Cassava Sciences Inc SAVA.O:

CASSAVA SCIENCES INC - FDA REQUIRES ADDITIONAL INFORMATION FROM CASSAVA FOR CLINICAL STUDY - SEC FILING

CASSAVA SCIENCES INC - PREPARES TO INITIATE PROOF-OF-CONCEPT STUDY IN FIRST HALF OF 2026 FOR SIMUFILAM - SEC FILING

CASSAVA SCIENCES INC - EXPECTS FORMAL LETTER FROM FDA DETAILING ISSUES ON CLINICAL TRIAL FOR SIMUFILAM - SEC FILING

Source text: [ID:n0001437749-25-036710]

Further company coverage: SAVA.O

 ((Reuters.Briefs@thomsonreuters.com;))